Ref. RPQ/REG/ISF/Alert N°1/2022

28 January 2022

Medical Product Alert

Falsified NANO CV-19 PATCH identified in WHO region of the Western Pacific

Alert Summary

This WHO Medical Product Alert refers to a falsified product called NANO CV-19 PATCH identified in Viet Nam and reported to WHO in December 2021.

The falsified product claims to "strengthen the immune system" to prevent infection with COVID-19. This product has not undergone any regulatory approval and therefore there is no scientific basis for this claim.

The product packaging carries the WHO logo and represents that it is endorsed or authorized by WHO. This falsified product is NOT authorized or endorsed by WHO. The use of the WHO logo on the packaging of the product is wholly unauthorized.

The packaging of the product also states that it is manufactured by a company called VAXXAS. VAXXAS has confirmed that they DO NOT manufacture this product and have NO products for sale anywhere in the world.

The logos of the US FDA and the pharmaceutical manufacturer MERCK are also printed on the packaging. The product is NOT authorized, endorsed, or manufactured by either organization.

The product identified in this Alert is falsified on the basis that it deliberately/fraudulently misrepresents its identity, composition, and source.

Table 1: Products subject of WHO Medical Product Alert

Product Name	NANO CV-19 PATCH
Stated manufacturer	VAXXAS
Batch / Lot	All batches/lots
Packaging language	English
Identified in	Viet Nam
Available Photos	Nano CV-19 Patch Strengthens immune support I was a supp

20, AVENUE APPIA - CH-1211 GENEVA 27 - SWITZERLAND - TEL CENTRAL +41 22 791 2111 - FAX CENTRAL +41 22 791 3111 - WWW.WHO.INT

Risks

Falsified COVID-19 vaccines and therapeutics pose a serious risk to global public health and place an additional burden on vulnerable populations and health systems.

The risk to patient health from the falsified product identified in this Alert may include delay in proper immunization with approved vaccines against COVID-19 and a false sense of protection that may lead to individuals not practising public health and social measures.

There is no evidence on the efficacy and safety of the product that could support its therapeutic claim. These products could be harmful or life-threatening in some circumstances. It is important to detect and remove these falsified products from circulation to prevent harm to patients.

Advice to regulatory authorities and the public

WHO requests increased surveillance and diligence within the supply chains of countries and regions likely to be affected by these falsified products.

All medical products must be approved and obtained from authorized/licensed suppliers. The products' authenticity and physical condition should be carefully checked. Seek advice from a healthcare professional when in doubt.

If you have these falsified products, please do not use them.

If you have used these products, or you suffered an adverse reaction/event after use, you are advised to seek immediate medical advice from a qualified healthcare professional and report the incident to the National Regulatory Authority or National Pharmacovigilance Centre.

National regulatory/health authorities are advised to immediately notify WHO if these falsified products are discovered in their country.

If you have any information concerning the manufacture or supply of these products, please inform WHO via rapidalert@who.int

WHO Global Surveillance and Monitoring System for Substandard and Falsified Medical Products
For more information, please visit our website. Email: rapidalert@who.int